Podcast Summary: Dr. Chapa’s OBGYN Clinical Pearls

Episode Title: Best ZMax Regimen for PPROM?
Date: March 8, 2026
Host: Dr. Chapa

Episode Overview

In this highly practical and engaging episode, Dr. Chapa tackles the confusing landscape of azithromycin (Zithromax) dosing for managing preterm prelabor rupture of membranes (PPROM). He walks listeners through the evolution of antibiotic regimens for PPROM, delves into the latest pharmacokinetic research (including a brand-new March 2026 study from AJOG, the “Gray Journal”), and ultimately offers food for thought on what might be the best evidence-based Zithromax regimen when erythromycin isn't an option.
The episode is aimed at medical professionals navigating real-world antibiotic decisions, illustrating both the controversies and the progress in clinical practice.

Key Discussion Points & Insights

1. Antibiotic Stewardship & Zithromax Misuse

• Dr. Chapa starts with some humor and antibiotic stewardship reminders, playing the NHS “antibiotic song” to highlight inappropriate use, especially of Zithromax.
• Quote: “People love their antibiotics. And one of the most misused antibiotics that we really do need to protect and safeguard because we need this joker to work is Zithromax.” (03:13)

2. PPROM: Historical Gold Standard Regimen

• The established first-line for PPROM latency:
  • IV ampicillin + erythromycin for 2 days, followed by oral amoxicillin + erythromycin for 5 days (total 7 days).
• Erythromycin is sometimes unavailable/tolerated poorly, leading to the use of azithromycin as an alternative.

3. The Controversy: What's the Best Zithromax Regimen?

a. Data Evolution:

• 2019 Retrospective Study:

  • No difference in latency between single-dose and multi-dose regimens.
  • Did not measure drug levels in amniotic fluid/uterus.
  • Slightly less neonatal respiratory distress with single-dose regimens, but with caveats.
  • Quote: “There was a little bit more respiratory distress among the five-day azithromycin group. So they said, hey look, you know what? Nothing really pans out one better than the other. But maybe, maybe in terms of less respiratory distress, maybe just give the single dose.” (05:34)

• 2024 Single-Center Study (Annals of Pharmacotherapy):

  • Higher rates of histological chorioamnionitis with single-dose vs. 5-day regimen (62% vs 46%).
  • Still unclear clinical correlations.

• 2025 Systematic Review:

  • Out of 17 reviewed guidelines, only 6 could confidently recommend a regimen.
  • “It's too ambiguous, we don’t really know. We need much more data.” (07:32)

b. March 2026 Pharmacokinetic Study—The Big News

• Study Setup:
  • Compared 1g single-dose vs. 500mg daily x 7 days.
  • Measured both maternal blood and amniotic fluid levels (using sanitary pads — non-invasive!).
  • Utilized simulation models to project amniotic fluid concentrations.
• Key Finding:
  500mg daily dosing for 7 days maintained higher, more consistent amniotic fluid concentrations above the MIC for urogenital pathogens than a single 1g bolus.
• Quote: “Daily azithromycin dosing at 500 milligrams daily for seven days ... maintained superior amniotic fluid concentration above the MIC for the most common genitourinary pathogens compared to the traditional 1 gram dose. So you do what you want to do.” (25:38)

c. Simulated Optimal Regimens (Based on Pharmacokinetics)

• Best approaches suggested by the study:

  • 1g loading dose, then 500mg daily for 6 more days
  • Alternative: 2g once, then 1g on days 2 and 4

• Reasoning: Single-dose strategy leads to early peak, but rapid drop-off in tissue/amnio levels. Daily/multi-dose regimens maintain effective levels throughout the week.

4. Caveats & Limitations

• N=18: Only 18 participants in the primary study. Very small sample.
• No Clinical Outcomes Measured:
  • The study is purely pharmacokinetic. No direct data on extended latency, reduced sepsis, or other neonatal outcomes.
  • Quote: “Did I mention anything about latency? Did I mention anything about neonatal sepsis? ... No, because that wasn’t what they checked. This literally was a pharmacokinetic pharmacodynamic study looking at blood levels and amniotic fluid levels. I don't know what happened, so take that for what you will.” (44:02)
• Special Finding:
  • Those on vaginal progesterone (n=3) had lower amniotic fluid azithromycin, suggesting a possible drug interaction or modulation—but with insufficient numbers for conclusions.

5. Practical Takeaways & Dr. Chapa’s Perspective

• Clinical Translation:

  • Higher amniotic drug levels may be beneficial for latency, but this remains undemonstrated until a clinical trial is done.
  • Evidence is now weighted toward multi-day dosing, especially daily 500mg, or a loading dose + daily, over one-time dosing.

• Proposed Practice Change:

  • For cases where erythromycin cannot be used, Dr. Chapa plans to advocate at his institution for:
    • 1g azithromycin loading, then 500mg daily x6 days (total 7 days), or
    • 500mg daily x7 days
    • (Always alongside standard ampicillin for GBS coverage.)
  • Quote: “So in cases or times where we cannot get erythromycin either by shortage or patient tolerance or whatever ... then we're gonna use Zithromax ... I'm gonna propose this because it does make sense. Although when my team's gonna ask me, what's the clinical outcomes? I'm gonna tell them what I told you. I have no idea, but it makes sense to me.” (45:52)

Timestamps for Important Segments

• 03:13 – Stewardship and Zithromax overuse: “One of the most misused antibiotics ... is Zithromax.”
• 05:34 – Overview of 2019 study (single vs. multi-dose, neonatal respiratory findings)
• 07:32 – Recap of practice guidelines confusion (2025 review)
• 09:34 – Introduction of March 2026 pharmacokinetic study
• 19:08 – Study design details (methods, population, sampling technique)
• 25:38 – Key findings: Daily 500mg superior to single 1g
• 28:27 – Simulated optimal regimens: “1 gram once, then 500 milligrams for six days, or alternative dosing ...”
• 35:05 – Limitations: Sample size, lack of clinical outcomes
• 39:45 – Odd finding: Vaginal progesterone may reduce amniotic azithromycin
• 44:02 – Big picture limitations and take-home message
• 45:52 – Dr. Chapa’s proposed regimen and practice implications

Notable Quotes

• On confusion in clinical practice:
  “Could you imagine a world where there's just no Zithromax? ... But we do need to protect this.” (03:21)
• On lack of standardization:
  “I’ve seen it, even in my own group. ... Some give 2 grams once and they're done. Some do 2 grams and then repeat it in three days with another 1 gram dose. ... And so, because there is no one uniform algorithm here ... everyone’s doing something different, but it’s better than nothing.” (13:05)
• On clinical evidence gap:
  “I read this whole paper. I’m like, oh, we can have better latency, maybe less fetal respiratory distress or whatever. ... Where’s the rest of it? Where’s the clinical stuff, bruh? I got nothing.” (44:35)

Conclusion

This episode highlights the continued ambiguity in the optimal use of azithromycin for PPROM when erythromycin isn't available, but showcases progress in understanding due to new pharmacokinetic data. Dr. Chapa both summarizes the evidence and models critical thinking for real-world practice—advocating reasoned change, while transparently acknowledging the ongoing need for actual clinical outcome research.

Recommendation
For clinicians facing erythromycin shortages/intolerance in PPROM management, consider:

• 1g azithromycin loading, then 500mg daily x6 days, or
• 500mg daily x7 days,
  — alongside standard GBS and latency coverage — but recognize definitive clinical outcome data is still pending.

Host: Dr. Chapa
Podcast: Dr. Chapa’s OBGYN Clinical Pearls
Episode: Best ZMax Regimen for PPROM?
Date: March 8, 2026